Food continues to be the most common trigger for anaphylaxis, a rapid-onset and potentially fatal hypersensitivity reaction, according to evidence presented at the AAAAI/WAO* Joint Congress 2018 held in Orlando, Florida, US.
A temporary increased dose of inhaled glucocorticoids did not reduce the rate of exacerbations in children with mild-to-moderate asthma, according to a study presented at the 2018 AAAAI/WAO congress held in Orlando, Florida, US.
The presence of higher levels of unmetabolized folic acid (UMFA) at birth was associated with the development of food allergy in children, according to a study presented at AAAAI/WAO Joint Congress 2018.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.